Navigation Links
Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results

CRANBURY, N.J., May 13 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) today reported its financial results for the third quarter ended March 31, 2008 and announced new strategic objectives as part of a restructuring of its clinical-stage product portfolio and development programs. Palatin will continue to develop products targeting melanocortin and natriuretic receptors in the sexual dysfunction, obesity, and cardiovascular fields, including acute hospital care products for use in treatment of acute systemic hypertension, congestive heart failure and hemorrhagic shock. The restructuring focuses the Company's resources on the programs and opportunities that management believes are most likely to increase shareholder value. Additional details will be provided by management in a conference call today at 11:00 a.m. Eastern Time.

Strategic Restructuring

Palatin has undertaken a strategic restructuring with the following elements and objectives:

-- Following a detailed evaluation, including review of regulatory and

commercial information and data on its new melanocortin compounds under

development for sexual dysfunction, Palatin has discontinued

development of bremelanotide for the treatment of male and female

sexual dysfunction;

-- Developing bremelanotide as a therapeutic drug for treatment of

hemorrhagic shock and related indications (shock induced by blood loss,

such as secondary to surgery or trauma);

-- Initiating a Phase 2A study this quarter with PL-3994, Palatin's

natriuretic peptide receptor A agonist compound, in patients with

controlled hypertension;

-- Initiating a Phase 2A study of PL-3994 during the next fiscal year for

treatment of acute congestive heart failure;

-- Advancing new Palatin compound PL-6983, which in animal models causes

significantly lower increases in blood pressure than seen with

bremelanotide, into Phase 1 clinical studies for treatment of male and

female sexual dysfunction;

-- Continuing its melanocortin receptor-based collaboration with

AstraZeneca AB on developing compounds for treating obesity; and

-- Effecting an immediate reduction in force of 30% of the Company's


"Palatin has had a strong and productive research effort focused on two challenging and exciting scientific areas: melanocortin and natriuretic peptide receptors. We have generated a substantial amount of data and an extensive product portfolio that allows us numerous exciting opportunities to drive value for our shareholders," stated Carl Spana, Ph.D., President and Chief Executive Officer of Palatin. Dr. Spana continued, "Concentrating our efforts on value drivers and matching our resources to those projects with the highest potential for near-term success is our immediate priority."

The Company believes that the staff reduction aligns the Company's human resources with its new strategic objectives and will allow the Company to effectively advance its development and clinical programs. The downsizing is expected to result in annual savings of approximately $3 million. Palatin will record an estimated $400,000 charge for severance and related costs in the quarter ending June 30, 2008. The Company, which ended the March 31, 2008 quarter with $17.6 million of cash, cash equivalents and available-for-sale investments, anticipates that the restructuring will reduce its cash burn rate to approximately $16 million over the next four quarters.

Financial Results

Palatin reported a net loss of $5.1 million, or $(0.06) per basic and diluted share, for the quarter ended March 31, 2008, compared to a net loss of $6.7 million, or $(0.09) per basic and diluted share, for the same period in 2007. Total revenues for the quarter ended March 31, 2008 were $747,000, compared to $3.1 million for the same period in 2007.

The decrease in the net loss for the quarter ended March 31, 2008 compared to the quarter ended March 31, 2007 was primarily attributable to the reduction in development expenses for bremelanotide, the Company's drug previously under development for the treatment of male and female sexual dysfunction.

For the quarter ended March 31, 2008, Palatin recognized $0.7 million of contract revenue related to its collaboration agreement with AstraZeneca AB. In the comparable quarter of 2007, Palatin recognized $3.1 million of contract revenue, primarily related to the reimbursement by King Pharmaceuticals, Inc. of bremelanotide development costs pursuant to the companies' collaboration agreement, which was terminated in the quarter ended September 30, 2007.

Total operating expenses for the quarter ended March 31, 2008 were $6.0 million, compared to $10.2 million for the comparable quarter of 2007, primarily due to lower development costs of bremelanotide.

Palatin's cash, cash equivalents and available-for-sale investments totaled $17.6 million as of March 31, 2008.

Conference Call / Webcast

The Company will host a conference call today at 11:00 a.m. Eastern Time to discuss its strategic restructuring and its third quarter financial results. Individuals interested in listening to the conference call live can dial 1-888-221-3884 (domestic) or 1-913-312-1433 (international). A live webcast of the call is available online at A telephone replay will also be available approximately one hour after the completion of the call. To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), passcode 1346503. The webcast and telephone reply will be available through May 20, 2008.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company primarily focused on discovering and developing targeted, receptor-specific peptide and small molecule therapeutics, including melanocortin ("MC")-based therapeutics. Therapeutics affecting the activity of the MC family of receptors may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, cachexia, hemorrhagic shock and inflammation-related diseases. The Company is exploring other receptor- specific therapeutics, including natriuretic peptide receptor A ("NPRA") agonist compounds for use in treatment of acute systemic hypertension, congestive heart failure and other diseases. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. The Company currently has collaborations with AstraZeneca and the Mallinckrodt division of Covidien. For additional information regarding Palatin, please visit Palatin Technologies' website at

Forward-looking Statements

Statements about the Company's future expectations, including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements shall be subject to the safe harbors created thereby. Palatin's actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to the Company's ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre-clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R), ability to protect its intellectual property, and other factors discussed in the Company's periodic filings with the Securities and Exchange Commission. The Company is not responsible for updating for events that occur after the date of this press release.


Consolidated Statements of Operations


Three Months Ended Nine Months Ended

March 31, March 31,

2008 2007 2008 2007


Licenses, grants

and contracts $746,957 $3,090,036 $10,467,523 $11,768,247


Research and

development 4,561,047 8,128,584 16,296,268 29,821,764

General and

administrative 1,480,167 2,021,734 5,468,229 5,239,142

Total operating

expenses 6,041,214 10,150,318 21,764,497 35,060,906

Loss from operations (5,294,257) (7,060,282) (11,296,974) (23,292,659)


Investment income 197,199 348,337 908,290 899,711

Interest expense (14,136) (9,223) (44,834) (32,411)

Total other income,

net 183,063 339,114 863,456 867,300

Loss before income

taxes (5,111,194) (6,721,168) (10,433,518) (22,425,359)

Income tax benefit - - 1,291,444 778,308

NET LOSS $(5,111,194) $(6,721,168) $(9,142,074) $(21,647,051)

Basic and diluted

net loss per

common share $(0.06) $(0.09) $(0.11) $(0.30)

Weighted average

number of common

shares outstanding

used in computing

basic and diluted

net loss per common

share 85,204,169 78,052,712 85,195,179 73,329,042


Consolidated Balance Sheets


March 31, June 30,

2008 2007


Current assets:

Cash and cash equivalents $14,223,326 $31,447,615

Available-for-sale investments 3,385,752 2,323,642

Accounts receivable 338,870 607,841

Prepaid expenses and other current assets 707,261 1,008,464

Total current assets 18,655,209 35,387,562

Property and equipment, net 5,478,267 6,070,226

Restricted cash 475,000 475,000

Other assets 58,926 848,446

Total assets $24,867,402 $42,781,234


Current liabilities:

Capital lease obligations and notes

payable, current portion $281,840 $216,841

Accounts payable 979,142 1,120,894

Accrued expenses 1,582,027 2,420,837

Accrued compensation 715,036 941,300

Deferred revenue, current portion 1,916,669 4,864,833

Total current liabilities 5,474,714 9,564,705

Capital lease obligations and notes

payable, net of current portion 180,371 275,126

Deferred rent, net of current portion 1,597,647 1,966,628

Deferred revenue, net of current portion 6,388,886 12,443,087

Total liabilities 13,641,618 24,249,546

Stockholders' equity:

Preferred stock of $.01 par value -

authorized 10,000,000 shares;

Series A Convertible; issued and

outstanding 4,997 shares as of

December 31, 2007 and June 30, 2007 50 50

Common stock of $.01 par value -

authorized 150,000,000 shares; issued

and outstanding 85,204,169 and

85,126,915 shares as of December 31,

2007 and June 30, 2007, respectively 852,042 851,269

Additional paid-in capital 207,648,737 205,875,438

Accumulated other comprehensive income 62,098 -

Accumulated deficit (197,337,143) (188,195,069)

Total stockholders' equity 11,225,784 18,531,688

Total liabilities and stockholders'

equity $24,867,402 $42,781,234

SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
2. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
3. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
4. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
5. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
6. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
7. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
8. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
9. Veran Medical Technologies Secures $4.75M in First Institutional Funding
10. Neurobiological Technologies Reports Third Quarter Financial Results
11. InSet Technologies Appoints Jon Tremmel to its Board of Directors
Post Your Comments:
(Date:10/11/2017)... , ... October 11, 2017 , ... ComplianceOnline’s Medical Device ... on 7th and 8th June 2018 in San Francisco, CA. The Summit brings together ... as several distinguished CEOs, board directors and government officials from around the world to ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Disappearing forests ... the lives of over 5.5 million people each year. Especially those living in larger ... startup Treepex - based in one of the most pollution-affected countries globally - decided ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
Breaking Biology Technology:
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
Breaking Biology News(10 mins):